Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein.
Matthijs P RaadsenChristine DahlkeAnahita FathiMart M LamersPetra van den DoelLuca M ZaeckMartin E van RoyenErwin de BruinReina SikkemaMarion P G KoopmansEric Cm van GorpGerd SutterRory D de VriesMarylyn M AddoBart L HaagmansPublished in: The Journal of infectious diseases (2023)
Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus (MPXV) and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome- associated coronavirus (MERS-CoV). Here, we report that cross-reactive MPXV nAbs were detectable in only a single subject after the first dose, 3 out of 10 after the 2nd dose, and in 10 out of 10 after the 3rd dose of MVA-MERS-S vaccine.